Dietary Supplement cGMP: 21 CFR Part 111 Requirements Explained

Overview of 21 CFR Part 111

The dietary supplement cGMP regulation, codified at 21 CFR Part 111, was established under the Dietary Supplement Health and Education Act of 1994 (DSHEA) and finalized in June 2007. The regulation applies to all domestic and foreign facilities that manufacture, package, label, or hold dietary supplements sold in the United States.

Part 111 is organized into subparts covering specific aspects of GMP:

• Subpart B — Personnel (§111.8–111.14)
• Subpart C — Physical plant and grounds (§111.15–111.23)
• Subpart D — Equipment and utensils (§111.25–111.35)
• Subpart E — Requirement to establish a production and process control system (§111.55–111.77)
• Subpart F — Production and process control system: requirements for quality control (§111.103–111.140)
• Subpart G — Production and process control system: requirements for components, packaging, and labels (§111.153–111.180)
• Subpart H — Production and process control system: requirements for the master manufacturing record (§111.205–111.210)
• Subpart I — Production and process control system: requirements for the batch production record (§111.255–111.260)
• Subpart J — Production and process control system: requirements for laboratory operations (§111.303–111.330)
• Subpart K — Production and process control system: requirements for manufacturing operations (§111.353–111.380)
• Subpart L — Production and process control system: requirements for packaging and labeling (§111.403–111.430)
• Subpart M — Holding and distributing (§111.453–111.477)
• Subpart N — Returned dietary supplements (§111.503–111.510)
• Subpart O — Product complaints (§111.553–111.570)
• Subpart P — Records and recordkeeping (§111.605–111.610)

Unlike food facility cGMPs under 21 CFR Part 117 (which evolved from Part 110), dietary supplement cGMPs under Part 111 have requirements that are more detailed and stringent, reflecting the unique risks associated with concentrated botanical and nutritional ingredients.

Identity Testing: The Most Critical Requirement

The most frequently cited cGMP violation in FDA dietary supplement inspections is failure to establish and follow component identity testing procedures (21 CFR §111.75(a)(1)). This requirement mandates that manufacturers must test or examine every incoming component (ingredient) to verify its identity before use in manufacturing.

What identity testing requires:

• 100% identity verification. Every lot of every incoming component must be tested for identity — not just a random sample of lots. You cannot rely solely on a Certificate of Analysis (CoA) from your supplier.
• Scientifically valid methods. Identity testing must use methods that are scientifically valid for the specific component. Common methods include HPTLC (High Performance Thin Layer Chromatography), HPLC, IR spectroscopy, DNA testing (for botanicals), and organoleptic evaluation (for some components).
• Written specifications. Each component must have a written identity specification that defines what constitutes a passing identity test (§111.70(b)).
• Qualified personnel. Identity testing must be performed or overseen by qualified individuals with appropriate training and experience (§111.12).

FDA has consistently emphasized that relying solely on a supplier's CoA without conducting independent identity testing is a cGMP violation. You may use CoAs to supplement your testing program, but they cannot replace it.

Specifications, Batch Records, and Documentation

Part 111 requires extensive documentation throughout the manufacturing process:

Written Specifications

You must establish written specifications for each component (raw material), in-process material, and finished product (§111.70). These specifications must include identity requirements and may include specifications for purity, strength, composition, and limits on contaminants.

Master Manufacturing Record (MMR)

Every dietary supplement product must have a Master Manufacturing Record (§111.205) that contains:

• Product name and a description of the dosage form
• Complete list of components and their quantities per batch
• Weight or measure of each component
• Identity and weight/measure of each component
• Statement of theoretical yield
• Written manufacturing instructions including processing parameters and in-process controls
• Packaging and labeling specifications

Batch Production Record (BPR)

For every batch manufactured, a Batch Production Record (§111.255) must be created that includes:

• Batch number and the date of manufacture
• Identity and weight of each component used
• Documentation of each manufacturing step performed
• In-process test results
• Initials or signatures of personnel who performed each step
• Actual yield vs. theoretical yield with explanation of any significant discrepancies
• Results of finished product testing

Personnel, Equipment, and Facility Requirements

Part 111 sets specific requirements for the people, equipment, and facilities involved in dietary supplement manufacturing:

Personnel (Subpart B)

• Qualified personnel. You must employ sufficient personnel with the education, training, and experience to manufacture, package, label, and hold dietary supplements (§111.12).
• Supervisory qualification. Supervisors must have the education, training, or experience to ensure proper manufacture.
• Hygiene requirements. Personnel must maintain adequate personal cleanliness and follow hygienic practices (§111.10). This includes requirements for handwashing, protective clothing, and illness reporting.
• Training records. You must maintain records of all training provided, including dates, topics, and attendees (§111.14).

Equipment (Subpart D)

• Equipment must be designed and installed to facilitate cleaning and maintenance (§111.25)
• Calibration must be performed at regular intervals using certified reference standards (§111.30)
• Equipment must be cleaned, maintained, and sanitized at appropriate intervals (§111.27)
• Automatic, mechanical, or electronic equipment must be inspected, checked, and calibrated to ensure proper performance (§111.35)

Physical Plant (Subpart C)

• Facilities must be designed to prevent contamination and mix-ups (§111.15)
• Adequate lighting, ventilation, and plumbing are required (§111.20)
• Separate areas or controls for different operations (receiving, manufacturing, packaging, storage) (§111.23)

Laboratory Operations and Quality Control

Part 111 requires that quality control operations be established and followed (Subpart F) and that laboratory operations meet specific standards (Subpart J):

• Quality control personnel. You must designate one or more qualified individuals as quality control personnel (§111.103). These individuals are responsible for approving or rejecting components, products, labels, and packaging.
• Laboratory controls. Testing must use validated or scientifically valid methods (§111.320). Equipment used for laboratory testing must be qualified, calibrated, and maintained.
• Reference standards. You must use appropriate reference standards for testing (§111.315).
• Reserve samples. You must retain reserve samples of each lot of packaged and labeled dietary supplements for at least 1 year past the shelf life or 2 years after distribution (§111.83).
• Out-of-specification results. When test results fall outside specifications, you must have procedures for investigation and disposition of the affected batch (§111.123).

CAPA and Complaint Handling

Corrective and Preventive Action (CAPA) is embedded throughout Part 111 as a fundamental quality system requirement:

• Product complaints (Subpart O): You must establish written procedures for reviewing and investigating product complaints (§111.553). Every complaint involving a possible failure to meet specifications must be investigated.
• Returned products (Subpart N): Returned dietary supplements must be quarantined and evaluated before any decision to reprocess, relabel, or destroy (§111.503).
• Corrective actions: When you identify a failure or discrepancy in your manufacturing process, you must take appropriate corrective action and document it (§111.77).
• Adverse event reporting: While Part 111 covers cGMP, dietary supplement companies also have separate adverse event reporting obligations under 21 CFR Part 4 (DSHEA) — serious adverse events must be reported to FDA within 15 business days.

Records related to complaints, investigations, corrective actions, and adverse events must be maintained for the longer of 1 year past shelf life or 2 years after distribution. Many companies maintain these records for longer periods as a risk management practice.

Foreign supplement manufacturers selling in the U.S. must comply with Part 111 and should also ensure their facility is properly registered with FDA and has a designated U.S. Agent.